Bullish & Foolish
Full GANX fundamentals All 466 on the Survival Watch

GANXGAIN THERAPEUTICS, INC

Is Gain Therapeutics struggling financially?

Yes, by its own account. Gain Therapeutics told the SEC on 11 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

  • Needs to raise money

    In addition, the impact of these events and conditions on our liquidity raise substantial doubt about our ability to continue as a going concern.

    Form 10-K, filed 26 Mar 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$87.5M
Source filing
10-Q 11 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 4months

    If the burn speeds up

    Empty by Oct 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$13.1M

÷

Cash burned over the last 12 months

$32.6M

What Gain Therapeutics told the SEC

…from the date these financial statements are issued. Because of the current liquidity situation and lack of expected revenues in the foreseeable future, substantial doubt exists about its ability to continue as a going concern. The Company will need to obtain additional capital and/or other funding in order to continue operations beyond the first quarter of 2027. Management plans to raise additional capital…

GAIN THERAPEUTICS, INC, Form 10-Q, filed 11 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 44.2% share-count increase The company issued stock. Each share now owns 30.6% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt